NCT06530719View on ClinicalTrials.gov

A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2028

Conditions
Lung NeoplasmsLung Cancer, Nonsmall Cell
Interventions
DRUG

Osimertinib mesylate

Osimertinib mesylate , 80mg QD，until the duration of treatment reaches 3 years, the disease progresses, or other treatment termination criteria are met

All Listed Sponsors
lead

Jin Ying

OTHER

NCT06530719 - A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery | Biotech Hunter | Biotech Hunter